This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, A. Articles by Lowe, G. Search for Related Content PubMed PubMed Citation Articles by Smith, A. Articles by Lowe, G. Related Collections Epidemiology Coagulation and fibronolysis Pathophysiology Risk Factors

(Circulation. 2005;112:3080-3087.)
© 2005 American Heart Association, Inc.

Epidemiology

Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke?

The Caerphilly Study

Ann Smith, PhD; Chris Patterson, PhD; John Yarnell, MD; Ann Rumley, PhD; Yoav Ben-Shlomo, PhD; Gordon Lowe, MD

From the Department of Epidemiology and Public Health (A.S., C.P., J.Y.), Queen’s University, Belfast, Northern Ireland; the Cardiovascular and Medical Division (A.R., G.L.), University of Glasgow, Glasgow, Scotland; and the Department of Social Medicine (Y.B.-S.), University of Bristol, Bristol, United Kingdom.

Correspondence to Dr J.W.G. Yarnell, Department of Epidemiology and Public Health, Queen’s University, Mulhouse Bldg, Grosvenor Rd, Belfast BT12 6BJ, UK. E-mail j.yarnell{at}qub.ac.uk

Received April 20, 2005; revision received July 29, 2005; accepted September 8, 2005.

Background— Few studies have examined whether hemostatic markers contribute to risk of coronary disease and ischemic stroke independently of conventional risk factors. This study examines 11 hemostatic markers that reflect different aspects of the coagulation process to determine which have prognostic value after accounting for conventional risk factors.

Methods and Results— A total of 2398 men aged 49 to 65 years were examined in 1984 to 1988, and the majority gave a fasting blood sample for assay of lipids and hemostatic markers. Men were followed up for a median of 13 years, and cardiovascular disease (CVD) events were recorded. There were 486 CVD events in total, 353 with prospective coronary disease and 133 with prospective ischemic stroke. On univariable analysis, fibrinogen, low activated protein C ratio, D-dimer, tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) were associated significantly with risk of CVD. On multivariable analyses with conventional risk factors forced into the proportional hazards model, fibrinogen, D-dimer, and PAI-1 were significantly associated with risk of CVD, whereas factor VIIc showed an inverse association (P=0.001). In a model that contained the conventional risk factors, the hazard ratio for subsequent CVD in the top third of the distribution of predicted risk relative to the bottom third was 2.7 for subjects without preexisting CVD. This ratio increased to 3.7 for the model that also contained the 4 hemostatic factors.

Conclusions— Fibrinogen, D-dimer, PAI-1 activity, and factor VIIc each has potential to increase the prediction of coronary disease/ischemic stroke in middle-aged men, in addition to conventional risk factors.

Key Words: coagulation • fibrinolysis • fibrinogen • coronary disease • stroke

This article has been cited by other articles:

				R. L.C. Hoo, W.S. Chow, M.H. Yau, A. Xu, A. W.K. Tso, H.F. Tse, C. H.Y. Fong, S. Tam, L. Chan, and K. S.L. Lam Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2777 - 2782. [Abstract] [Full Text] [PDF]

				P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2250 - 2257. [Abstract] [Full Text] [PDF]

				J. Sanz, P. R. Moreno, and V. Fuster The Year in Atherothrombosis J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1740 - 1749. [Full Text] [PDF]

				P.E. Morange, C. Bickel, V. Nicaud, R. Schnabel, H.J. Rupprecht, D. Peetz, K.J. Lackner, F. Cambien, S. Blankenberg, L. Tiret, et al. Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease: The AtheroGene Study Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2793 - 2799. [Abstract] [Full Text] [PDF]

				M.-C. Alessi and I. Juhan-Vague PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2200 - 2207. [Abstract] [Full Text] [PDF]

				S. Kathiresan, Q. Yang, M. G. Larson, A. L. Camargo, G. H. Tofler, J. N. Hirschhorn, S. B. Gabriel, and C. J. O'Donnell Common Genetic Variation in Five Thrombosis Genes and Relations to Plasma Hemostatic Protein Level and Cardiovascular Disease Risk Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1405 - 1412. [Abstract] [Full Text] [PDF]